Photo of Professionals at the Brandi Law Firm.

We Are Here To Help You Through Your Most Difficult Times

  1. Home
  2.  – 
  3. Drug and Medical Device Litigation
  4.  – Big Pharma Fined $3.75 Billion in Fraud Penalties in Fiscal 2013

Big Pharma Fined $3.75 Billion in Fraud Penalties in Fiscal 2013

| Mar 3, 2014 | Drug and Medical Device Litigation

According to the U.S. Departments of Justice and Health and Human Services, these departments recovered $4.3 billion in criminal and civil fines in the 2013 fiscal year, which ended in September 2013.  This is a $100 million increase from the 2012 fiscal year.  The five-year total in fines has now reached $19.2 billion.  Pharma drugmakers in 2013 tallied $3.75 billionnearly 87% of the total.

Click here to read the full article: Pharma Shelled out $3.75B in Fraud Penalties in Record-Setting Year, Feds Say

The top 5 fines for the fiscal year were:

1.         Abbott Laboratories was fined $1.5 billion for off label allegations of the seizure drug, Depakote.

2.         Amgen paid $762 million to settle marketing violations.

3.         Ranbaxy Laboratories settled for $500 million for violating manufacturing standards and outright lying to the FDA.

4.         A $490.9 million settlement agreement with Pfizer’s Wyeth unit related to illegal marketing of a kidney-transplant prescription medication, Rapamune (sirolimus).

5.         A $109 million fine was issued to Sanofi units to settle Hyalgan kickback allegations.

The 2014 fiscal year may have just started in October, but big pharma has already notched two major fines.  First, Johnson & Johnson was fined $2.2 billion for improperly marketing their drug Risperdal.  Most recently, Endo Health Solutions settled for $192.7 million to resolve Lipoderm off label use.

The practices of improper marketing and failure to warn are at the heart of the current DePuy and transvaginal mesh litigation that Johnson & Johnson faces.  Drug manufacturers have historically been shown to engage in improper marketing practices, paying kickbacks to prescribers, concealing essential information consumers and their physicians need to know, denying all of that conduct beyond scores of corporate attorneys in litigation, then attempting to quietly settle the concealment and improper marketing claims with the federal or State authorities once the civil litigation has drawn near a close.

Contact Our Experienced San Francisco Drug Recall Lawyers Today

At The Brandi Law Firm, we help people throughout the country who have been harmed because of a defective drug or medical device such as women contracting type two diabetes while using Lipitor, people suffering from bladder cancer while using Actos, Fosamax users suffering atypical femur fractures, DePuy ASR hip users requiring revisions or suffering toxic poisoning, and women suffering significant pain, erosion and removal of vaginal mesh.  Instead of treating all victims of defective drugs and medical devices the same we take a different, more personalized approach with a team of experienced defective drug attorneys and paralegals working for every client.  Our goal is to provide you with information about your legal options and to help you pursue compensation and holding these drug companies responsible for their dangerous actions.  Please contact The Brandi Law Firm today (1-800-481-1615 or email us) to talk with the experienced San Francisco defective drug attorneys.

Trademark Notice

Abbott Laboratories, Amgen, Ranbaxy Laboratories, Pfizer, Werth, Sanofi, Johnson & Johnson, and Endo Health Solutions are registered trademarks.  The use of these trademarks is solely for product identification and informational purposes.  These trademarks are not affiliated with this website, and the trademarks have no affiliation with The Brandi Law Firm.  Nothing on this site has been authorized or approved by the trademarks.